Supernus Pharmaceuticals Appoints Frank Mottola as Chief Technical Operations Officer.
ByAinvest
Monday, Aug 4, 2025 8:12 am ET1min read
SUPN--
Mottola brings extensive experience in quality and operations to the role. His appointment comes at a critical juncture for Supernus, as the company continues to expand its portfolio and diversify its revenue streams through strategic acquisitions and product development. Mottola’s leadership will be instrumental in driving operational excellence and technological innovation, which are key to achieving the company’s growth objectives.
The appointment of Mottola follows Supernus’s recent acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE), which added the innovative commercial product ZURZUVAE® (zuranolone) and a novel CNS discovery platform to the company’s portfolio. This acquisition is expected to accelerate mid- to long-term revenue and cash flow growth and further diversify the revenue base [1].
Mottola’s role will be crucial in integrating the new assets and ensuring smooth operations as Supernus continues to expand its footprint in the neuropsychiatric conditions market. His background in quality and GMP operations will be particularly valuable in maintaining the high standards required for the development and commercialization of CNS therapies.
Supernus has been making significant strides in its strategic development, with a focus on diversifying its revenue streams and enhancing its product pipeline. The appointment of Mottola aligns with these strategic goals and underscores the company’s commitment to operational excellence and innovation.
References:
[1] https://www.biospace.com/press-releases/supernus-pharmaceuticals-completes-acquisition-of-sage-therapeutics
Supernus Pharmaceuticals has appointed Frank Mottola as Chief Technical Operations Officer, effective June 16, 2025. Mottola, previously the company's Senior Vice President of Quality, GMP Operations and IT, was recommended by the Compensation Committee and approved by the Board of Directors.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) has announced the appointment of Frank Mottola as its Chief Technical Operations Officer, effective June 16, 2025. Mottola, previously serving as Senior Vice President of Quality, GMP Operations and IT, has been recommended by the Compensation Committee and approved by the Board of Directors.Mottola brings extensive experience in quality and operations to the role. His appointment comes at a critical juncture for Supernus, as the company continues to expand its portfolio and diversify its revenue streams through strategic acquisitions and product development. Mottola’s leadership will be instrumental in driving operational excellence and technological innovation, which are key to achieving the company’s growth objectives.
The appointment of Mottola follows Supernus’s recent acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE), which added the innovative commercial product ZURZUVAE® (zuranolone) and a novel CNS discovery platform to the company’s portfolio. This acquisition is expected to accelerate mid- to long-term revenue and cash flow growth and further diversify the revenue base [1].
Mottola’s role will be crucial in integrating the new assets and ensuring smooth operations as Supernus continues to expand its footprint in the neuropsychiatric conditions market. His background in quality and GMP operations will be particularly valuable in maintaining the high standards required for the development and commercialization of CNS therapies.
Supernus has been making significant strides in its strategic development, with a focus on diversifying its revenue streams and enhancing its product pipeline. The appointment of Mottola aligns with these strategic goals and underscores the company’s commitment to operational excellence and innovation.
References:
[1] https://www.biospace.com/press-releases/supernus-pharmaceuticals-completes-acquisition-of-sage-therapeutics
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet